Capecitabine in the Treatment of Advanced Gastric Cancer

Jae-Lyun Lee; Yoon-Koo Kang


Future Oncol. 2008;4(2):179-198. 

In This Article

Regulatory Affairs

Capecitabine is now approved for use in gastric cancer in the following countries: EU Member States, Norway, Iceland, Paraguay, Nicarágua, Aruba, Bahrain, Bangladesh, Bolívia, Cambodia, Chile, Dominican Republic, Ecuador, Israel, Republic of Korea, México, Moldova, Philippines, Trinidad and Tobago and Venezuela. In the EU, capecitabine is indicated for first-line treatment of AGC when combined with a platinum-based regimen. An application to the US FDA for its use in the USA is pending.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.